Patents by Inventor John V Heymach

John V Heymach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220143023
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 12, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jacqulyne ROBICHAUX, Monique NILSSON, John V. HEYMACH
  • Publication number: 20220041751
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have a HER2 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib, in combination with a HER2 anti-body-drug conjugate.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 10, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: John V. HEYMACH, Jacqulyne ROBICHAUX, Monique NILSSON
  • Publication number: 20210361655
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have a HER2 exon 19 mutation, such as a point mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib.
    Type: Application
    Filed: March 27, 2019
    Publication date: November 25, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jacqulyne ROBICHAUX, John V. HEYMACH
  • Publication number: 20210062274
    Abstract: Provided herein are methods for determining a subtype of a small cell lung cancer in a patient based on the express status of ASCL1, NEUROD1, and POU2F3, which are expressed in a mutually exclusive fashion. The subtype of the cancer can be used to determine the sensitivity of the cancer to certain anti-cancer therapies. As such, also provided are methods of treating patients having small cell lung cancer based on the subtyping results.
    Type: Application
    Filed: September 3, 2020
    Publication date: March 4, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: Carl M. GAY, Lauren A. BYERS, John V. HEYMACH
  • Publication number: 20210015819
    Abstract: The present disclosure provides methods for treating cancer in a patient determined to have an EGFR activating mutation by administering a CDK inhibitor and/or SAC component inhibitor.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 21, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: John V. HEYMACH, Monique NILSSON, Jacqulyne ROBICHAUX
  • Publication number: 20200316071
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.
    Type: Application
    Filed: November 17, 2017
    Publication date: October 8, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jacqulyne ROBICHAUX, Monique NILSSON, John V. HEYMACH
  • Publication number: 20140155397
    Abstract: EMT signatures and markers useful for characterizing the status of epithelial cancers and for predicting drug responses in patients having non-small cell lung cancer are provided together with methods of using the same.
    Type: Application
    Filed: April 2, 2012
    Publication date: June 5, 2014
    Applicant: Board of Regents
    Inventors: John V Heymach, Jing Wang, Lauren Averett Byers, Kevin R. Coombes, John D. Minna, Luc Girard